These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31034476)

  • 1. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis.
    Bajaj NS; Vaduganathan M; Qamar A; Gupta K; Gupta A; Golwala H; Butler J; Goldhaber SZ; Mehra MR
    PLoS Med; 2019 Apr; 16(4):e1002797. PubMed ID: 31034476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Cohen JM; Emed J; Tagalakis V; Roussin A; Geerts W
    Cochrane Database Syst Rev; 2013 Jul; (7):CD008201. PubMed ID: 23861035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
    Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
    Liew AY; Piran S; Eikelboom JW; Douketis JD
    J Thromb Thrombolysis; 2017 Apr; 43(3):291-301. PubMed ID: 27900627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Arthroscopic Surgery and Anterior Cruciate Ligament Reconstruction: A Meta-analysis of Randomized Controlled Trials.
    Zhu J; Jiang H; Marshall B; Li J; Tang X
    Am J Sports Med; 2019 Jul; 47(8):1994-2002. PubMed ID: 30113231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
    Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
    Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
    Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.
    Sardar P; Chatterjee S; Mukherjee D
    Drugs; 2013 Jul; 73(11):1171-82. PubMed ID: 23812923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials.
    Zayed Y; Kheiri B; Barbarawi M; Banifadel M; Abdalla A; Chahine A; Obeid M; Haykal T; Yelangi A; Malapati S; Bachuwa G; Seedahmed E
    Intern Med J; 2020 Feb; 50(2):192-199. PubMed ID: 31276276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Venous Thromboembolism and Benefits and Risks of Thromboprophylaxis After Cardiac Surgery: A Systematic Review and Meta-Analysis.
    Ho KM; Bham E; Pavey W
    J Am Heart Assoc; 2015 Oct; 4(10):e002652. PubMed ID: 26504150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
    Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
    J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
    Wang Y; Wang M; Ni Y; Liang Z
    Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
    [No Abstract]   [Full Text] [Related]  

  • 19. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?
    Sharma A; Chatterjee S; Lichstein E; Mukherjee D
    J Thromb Haemost; 2012 Oct; 10(10):2053-60. PubMed ID: 22863355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.